Genome-wide association study of monoamine metabolite levels in human cerebrospinal fluid

Molecular Psychiatry

Volumn 19, Issue 2, 2014, Pages 228-234

  Luykx, J J ^a,b   Bakker, S C ^a   Lentjes, E ^b   Neeleman, M ^a   Strengman, E ^b   Mentink, L ^a,b   Deyoung, J ^c   De Jong, S ^c   Sul, J H ^d   Eskin, E ^d,e   Van Eijk, K ^b   Van Setten, J ^b   Buizer Voskamp, J E ^a   Cantor, R M ^e   Lu, A ^e   Van Amerongen, M ^f   Van Dongen, E P A ^g   Keijzers, P ^h   Kappen, T ^b   Borgdorff, P ⁱ   Bruins, P ^g   Derks, E M ^j   Kahn, R S ^a   Ophoff, R A ^a,c,e   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Tergooi Hospitals   (Netherlands)

^g ST ANTONIUS HOSPITAL   (Netherlands)

^h CENTRAL MILITARY HOSPITAL   (Netherlands)

ⁱ DEPARTMENT OF SURGERY   (Netherlands)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DNA; GLUTAMATE RECEPTOR; MESSENGER RNA; MONOAMINE; SEROTONIN; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; PHOSPHODIESTERASE; PHOSPHODIESTERASE 9A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; METABOLITE; MIDDLE AGED; POST HOC ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ALLELE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CSMD1 GENE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN EXPERIMENT; NEUROTRANSMISSION; NORMAL HUMAN; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SSTR1 GENE;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ADULT; BIOGENIC MONOAMINES; CHROMOSOMES, HUMAN, PAIR 11; FEMALE; GENE EXPRESSION; GENETIC LOCI; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPING TECHNIQUES; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; LINEAR MODELS; MALE; MEMBRANE PROTEINS; MENTAL DISORDERS; METHOXYHYDROXYPHENYLGLYCOL; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84893658006     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.183     Document Type: Article

References (67)

1. Freimer N, Sabatti C. The human phenome project. Nat Genet 2003; 34: 15-21.
2. Bilder RM, Sabb FW, Cannon TD, London ED, Jentsch JD, Parker DS et al. Phenomics: the systematic study of phenotypes on a genome-wide scale. Neuroscience 2009; 164: 30-42.
3. Erhardt A, Czibere L, Roeske D, Lucae S, Unschuld PG, Ripke S et al. TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry 2011; 16: 647-663.
4. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR et al. Genome-wide association study of major depressive disorder: new results, metaanalysis, and lessons learned. Mol Psychiatry 2012; 17: 36-48.
5. Neale BM, Medland SE, Ripke S, Asherson P, Franke B, Lesch KP et al. Meta-analysis of genome-wide association studies of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010; 49: 884-897.
6. Owen MJ, Craddock N, Jablensky A. The genetic deconstruction of psychosis. Schizophr Bull 2007; 33: 905-911.
7. Glahn DC, Curran JE, Winkler AM, Carless MA, Kent Jr JW, Charlesworth JC et al. High dimensional endophenotype ranking in the search for major depression risk genes. Biol Psychiatry 2012; 71: 6-14.
8. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003; 361: 417-419.
9. Hyland K. Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid. Clin Chem 2008; 54: 633-641.
10. Harrison BJ, Olver JS, Norman TR, Burrows GD, Wesnes KA, Nathan PJ. Selective effects of acute serotonin and catecholamine depletion on memory in healthy women. J Psychopharmacol 2004; 18: 32-40.
11. Kurian MA, Gissen P, Smith M, Heales Jr. S, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011; 10: 721-733.
12. Naumann M, Gotz M, Reiners K, Lange KW, Riederer P. Neurotransmitters in CSF of idiopathic adult-onset dystonia: reduced 5-HIAA levels as evidence of impaired serotonergic metabolism. J Neural Transm 1996; 103: 1083-1091.
13. Assmann B, Kohler M, Hoffmann GF, Heales S, Surtees R. Selective decrease in central nervous system serotonin turnover in children with dopa-nonresponsive dystonia. Pediat Res 2002; 52: 91-94.
14. Freimer NB, Service SK, Ophoff RA, Jasinska AJ, McKee K, Villeneuve A et al. A quantitative trait locus for variation in dopamine metabolism mapped in a primate model using reference sequences from related species. Proc Natl Acad Sci USA 2007; 104: 15811-15816.
15. Higley JD, Thompson WW, Champoux M, Goldman D, Hasert MF, Kraemer GW et al. Paternal and maternal genetic and environmental contributions to cerebrospinal fluid monoamine metabolites in rhesus monkeys (Macaca mulatta). Arch Gen Psychiatry 1993; 50: 615-623.
16. Rogers J, Martin LJ, Comuzzie AG, Mann JJ, Manuck SB, Leland M et al. Genetics of monoamine metabolites in baboons: overlapping sets of genes influence levels of 5-hydroxyindolacetic acid, 3-hydroxy-4-methoxyphenylglycol, and homovanillic acid. Biol Psychiatry 2004; 55: 739-744.
17. Ducci F, Newman TK, Funt S, Brown GL, Virkkunen M, Goldman D. A functional polymorphism in the MAOA gene promoter (MAOA-LPR) predicts central dopamine function and body mass index. Mol Psychiatry 2006; 11: 858-866.
18. Jonsson EG, Norton N, Gustavsson JP, Oreland L, Owen MJ, Sedvall GC. A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res 2000; 34: 239-244.
19. Jonsson EG, Bah J, Melke J, Abou Jamra R, Schumacher J, Westberg L et al. Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers. BMC Psychiatry 2004; 4: 4.
20. Kishida I, Aklillu E, Kawanishi C, Bertilsson L, Agren H. Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression. Neuropsychopharmacology 2007; 32: 2143-2151.
21. Luykx JJ, Vinkers CH, Bakker SC, Visser WF, van Boxmeer L, Strengman E et al. A common variant in ERBB4 regulates GABA concentrations in human cerebrospinal fluid. Neuropsychopharmacology 2012; 37: 2088-92.
22. Luykx JJ, Bakker SC, Lentjes E, Boks MP, van Geloven N, Eijkemans MJ et al. Season of sampling and season of birth influence serotonin metabolite levels in human cerebrospinal fluid. PLoS One 2012; 7: e30497.
23. Gieger C, Geistlinger L, Altmaier E, Hrabe de Angelis M, Kronenberg F, Meitinger T et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet 2008; 4: e1000282.
24. Suhre K, Wallaschofski H, Raffler J, Friedrich N, Haring R, Michael K et al. A genome- wide association study of metabolic traits in human urine. Nat Genet 2011; 43: 565-569.
25. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
26. Browning SR, Browning BL. Rapid and accurate haplotype phasing and missingdata inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet 2007; 81: 1084-1097.
27. Howie BFC, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44: 955-9.
28. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010; 34: 816-834.
29. Johansson B, Roos BE. Concentrations of monoamine metabolites in human lumbar and cisternal cerebrospinal fluid. Acta Neurol Scand 1975; 52: 137-144.
30. Malm J, Kristensen B, Ekstedt J, Wester P. CSF concentration gradients of monoamine metabolites in patients with hydrocephalus. J Neurol Neurosurg Psychiatry 1994; 57: 1026-1033.
31. Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 2008; 32: 227-234.
32. Purcell S, Cherny SS, Sham PC. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19: 149-150.
33. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24: 1547-1548.
34. Lin SM, Du P, Huber W, Kibbe WA. Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 2008; 36: e11.
35. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article 3.
36. Smyth GK. Limma: linear models for microarray data. In: R Gentleman, V Carey, S Dudoit, R Irizarry, W Huber (eds). Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer: New York, 2005, pp 397-420.
37. Lu AT, Bakker S, Janson E, Cichon S, Cantor RM, Ophoff RA. Prediction of serotonin transporter promoter polymorphism genotypes from single nucleotide polymorphism arrays using machine learning methods. Psychiatr Genet 2012; 22: 182-188.
38. Haavik J, Blau N, Thony B. Mutations in human monoamine-related neurotransmitter pathway genes. Hum Mutat 2008; 29: 891-902.
39. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011; 43: 969-976.
40. Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF et al. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther 2012; 341: 396-409.
41. Bruno JF, Xu Y, Song J, Berelowitz M. Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc Natl Acad Sci USA 1992; 89: 11151-11155.
42. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234-242.
43. Lee MT, Chen CH, Lee CS, Chen CC, Chong MY, Ouyang WC et al. Genome-wide association study of bipolar I disorder in the Han Chinese population. Mol Psychiatry 2011; 16: 548-556.
44. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005; 11: 1214-1221.
45. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009; 459: 569-573.
46. Havik B, Le Hellard S, Rietschel M, Lybaek H, Djurovic S, Mattheisen M et al. The complement control-related genes CSMD1 and CSMD2 associate to schizophrenia. Biol Psychiatry 2011; 70: 35-42.
47. Edwards AC, Aliev F, Bierut LJ, Bucholz KK, Edenberg H, Hesselbrock V et al. Genome-wide association study of comorbid depressive syndrome and alcohol dependence. Psychiatr Genet 2012; 22: 31-41.
48. Kim HG, Kishikawa S, Higgins AW, Seong IS, Donovan DJ, Shen Y et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet 2008; 82: 199-207.
49. Finn JT, Grunwald ME, Yau KW. Cyclic nucleotide-gated ion channels: an extended family with diverse functions. Annu Rev Physiol 1996; 58: 395-426.
50. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006; 5: 660-670.
51. Reierson GW, Mastronardi CA, Licinio J, Wong ML. Repeated antidepressant therapy increases cyclic GMP signaling in rat hippocampus. Neurosci Lett 2009; 466: 149-153.
52. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. Neurosci 1999; 19: 610-618.
53. Reierson GW, Guo S, Mastronardi C, Licinio J, Wong ML. cGMP signaling, phosphodiesterases and major depressive disorder. Curr Neuropharmacol 2011; 9: 715-727.
54. Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 2006; 103: 15124-15129.
55. Esposito K, Reierson GW, Luo HR, Wu GS, Licinio J, Wong ML. Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med 2009; 41: 177-185.
56. van Staveren WC, Glick J, Markerink-van Ittersum M, Shimizu M, Beavo JA, Steinbusch HW et al. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J Neurocytol 2002; 31: 729-741.
57. Andreeva SG, Dikkes P, Epstein PM, Rosenberg PA. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J Neurosci 2001; 21: 9068-9076.
58. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 2005; 68: 1775-1781.
59. Verhoest PR, Proulx-Lafrance C, Corman M, Chenard L, Helal CJ, Hou X et al. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. J Med Chem 2009; 52: 7946-7949.
60. Hutson PH, Finger EN, Magliaro BC, Smith SM, Converso A, Sanderson PE et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4- methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H- py ran-4-yl)-1,5- dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 2011; 61: 665-676.
61. Small KS, Hedman AK, Grundberg E, Nica AC, Thorleifsson G, Kong A et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet 2011; 43: 561-564.
62. Grieve IC, Dickens NJ, Pravenec M, Kren V, Hubner N, Cook SA et al. Genome-wide co-expression analysis in multiple tissues. PLoS One 2008; 3: e4033.
63. Glinskii AB, Ma J, Ma S, Grant D, Lim CU, Sell S et al. Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders. Cell Cycle 2009; 8: 3925-3942.
64. Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikainen LP et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012; 44: 269-276.
65. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 2011; 40: 387-426.
66. Hetsroni I, Lyman S, Do H, Mann G, Marx RG. Symptomatic pulmonary embolism after outpatient arthroscopic procedures of the knee: the incidence and risk factors in 418,323 arthroscopies. J Bone Joint Surg Br 2011; 93: 47-51.
67. Luykx JJ, Laban KG, van den Heuvel MP, Boks MP, Mandl RC, Kahn RS et al. Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings. Neurosci Biobehav Rev 2012; 36: 198-205.